Abstract
Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis. See related article by Hiller et al., p. 1803.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1781-1783 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 26 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 15 2020 |
Bibliographical note
Publisher Copyright:© 2020 American Association for Cancer Research.
Keywords
- Biomarkers
- Breast Neoplasms
- Cell Line, Tumor
- Cell Proliferation
- Epithelial-Mesenchymal Transition
- Humans
- Propranolol
- Tumor Microenvironment
PubMed: MeSH publication types
- Comment
- Research Support, Non-U.S. Gov't
- Journal Article
